A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable advanced or recurrent gastric, gastroesophageal junction cancer or esophageal adenocarcinoma (GENTLE-Z).

被引：0

作者：

Okunaka, Mashiro

Furuoka, Momoka

Wakabayashi, Masashi

Furuya, Hideki

Bando, Hideaki

Shitara, Kohei

Nakayama, Izuma

机构：

[1] Natl Canc Ctr Hosp East, Dept Pharm, Kashiwa, Japan

[2] Natl Canc Ctr Hosp East, Kashiwa, Japan

[3] Natl Canc Ctr Hosp East, Div Promot Drug & Diag Dev, Kashiwa, Japan

[4] Natl Canc Ctr Hosp East, Clin Res Support Off, Kashiwa, Japan

[5] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan

[6] Natl Canc Ctr Hosp East, Gastrointestinal Oncol Dept, Kashiwa, Japan

[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.TPS504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS504 / TPS504

页数：1

共 41 条